Compounds > n-methyl-3,4-methylenedioxyamphetamine
Page last updated: 2024-10-21

n-methyl-3,4-methylenedioxyamphetamine and Developmental Disabilities

n-methyl-3,4-methylenedioxyamphetamine has been researched along with Developmental Disabilities in 3 studies

N-Methyl-3,4-methylenedioxyamphetamine: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
3,4-methylenedioxymethamphetamine : A member of the class of benzodioxoles that is 1,3-benzodioxole substituted by a 2-(methylamino)propyl group at position 5.

Developmental Disabilities: Disorders in which there is a delay in development based on that expected for a given age level or stage of development. These impairments or disabilities originate before age 18, may be expected to continue indefinitely, and constitute a substantial impairment. Biological and nonbiological factors are involved in these disorders. (From American Psychiatric Glossary, 6th ed)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Kisely, S1
Connor, M1
Somogyi, AA1
Siskind, D1
Singer, LT2
Moore, DG2
Min, MO2
Goodwin, J2
Turner, JJ2
Fulton, S2
Parrott, AC2

Reviews

1 review available for n-methyl-3,4-methylenedioxyamphetamine and Developmental Disabilities

ArticleYear
A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders.
    The Australian and New Zealand journal of psychiatry, 2023, Volume: 57, Issue:3

    Topics: Adult; Anxiety Disorders; Child; Cognitive Behavioral Therapy; Developmental Disabilities; Humans; N

2023

Other Studies

2 other studies available for n-methyl-3,4-methylenedioxyamphetamine and Developmental Disabilities

ArticleYear
Developmental outcomes of 3,4-methylenedioxymethamphetamine (ecstasy)-exposed infants in the UK.
    Human psychopharmacology, 2015, Volume: 30, Issue:4

    Topics: Adult; Age Factors; Child Development; Developmental Disabilities; Female; Hallucinogens; Humans; In

2015
One-year outcomes of prenatal exposure to MDMA and other recreational drugs.
    Pediatrics, 2012, Volume: 130, Issue:3

    Topics: Cognition; Developmental Disabilities; Dose-Response Relationship, Drug; Female; Hallucinogens; Huma

2012